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The fragile X premutation is a CGG trinucleotide repeat expansion between 55 and 200 repeats in the 5′-
untranslated region of the fragile X mental retardation 1 (FMR1) gene. Human carriers of the premutation
allele are at risk of developing the late-onset neurodegenerative disorder, fragile X-associated tremor/ataxia
syndrome (FXTAS). Characteristic neuropathology associated with FXTAS includes intranuclear inclusions in
neurons and astroglia. Previous studies recapitulated these histopathological features in neurons in a knock-in
mouse model, but without significant astroglial pathology. To determine the role of astroglia in FXTAS, we
generated a transgenic mouse line (Gfa2-CGG99-eGFP) that selectively expresses a 99-CGG repeat expansion
linked to an enhanced green fluorescent protein (eGFP) reporter in astroglia throughout the brain, including
cerebellar Bergmann glia. Behaviorally these mice displayed impaired motor performance on the ladder-rung
test, but paradoxically better performance on the rotarod. Immunocytochemical analysis revealed that CGG99-
eGFP co-localized with GFAP and S-100ß, but not with NeuN, Iba1, or MBP, indicating that CGG99-eGFP
expression is specific to astroglia. Ubiquitin-positive intranuclear inclusions were found in eGFP-expressing glia
throughout the brain. In addition, intracytoplasmic ubiquitin-positive inclusions were found outside the nucleus in
distal astrocyte processes. Intriguingly, intranuclear inclusions, in the absence of eGFP mRNA and eGFP fluorescence,
were present in neurons of the hypothalamus and neocortex. Furthermore, intranuclear inclusions in both neurons and
astrocytes displayed immunofluorescent labeling for the polyglycine peptide FMRpolyG, implicating FMRpolyG in the
pathology found in Gfa2-CGG99 mice. Considered together, these results show that Gfa2-CGG99 expression in mice is
sufficient to induce key features of FXTAS pathology, including formation of intranuclear inclusions, translation of
FMRpolyG, and deficits in motor function.
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The fragile X premutation is defined as an expanded
(CGG)n trinucleotide repeat in the 5′-untranslated re-
gion of the FMR1 gene. Clinical and genetic studies of
patients have indicated that carriers of the premutation
allele, defined as a repeat length between 55 and 200
CGGs, are at risk of developing the late-onset neurode-
generative disorder, fragile X-associated tremor/ataxia
syndrome (FXTAS) [27, 28, 35]. Elevated FMR1 mRNA
levels found in cells of premutation carriers support the
concept of a “toxic” mRNA gain-of-function mechanism
of pathophysiology in FXTAS [25], likely via sequestra-
tion of RNA-binding proteins by expanded CGG repeat-
containing RNA [48]. Repeat-associated non-ATG
translation (RAN) of a toxic in polyglycine-containing
peptide, FMRpolyG, from the expanded-repeat mRNA
may also contribute to FXTAS pathology [36, 47]. The
principal clinical symptoms of FXTAS include progres-
sive intention tremor and ataxia, peripheral neuropathy,
neuropsychological involvement (anxiety, depression),
and cognitive impairments and dementia at late stages
of the disorder [4, 25, 26]. Radiologic changes observed
by MRI include increased T2 signal (hyperintensities) in
cerebral white matter and in the middle cerebellar ped-
uncle (the “MCP sign”), as well as global brain atrophy
[8]. Levels of FMR1 mRNA are elevated and levels of
FMRP are slightly decreased in FXTAS. The neuro-
pathological hallmark of FXTAS is the presence of
spherical eosinophilic intranuclear inclusions in neurons
and astroglia throughout the brain that are immunoreac-
tive for ubiquitin [23, 24, 51].
The CGG KI mouse model of FXTAS shows similar
neurobehavioral features that appear to be similar to
those in FXTAS [20]. These include gait ataxia and
visuomotor deficits in the ladder-rung [31] and rotarod
tests [54], anxiety in the open field [10] and cognitive
impairment [30, 32]. They also show ubiquitin-positive
spherical inclusions in neurons and astrocytes similar to
those found in FXTAS brains [6, 56]. The inclusions are
found throughout the brain in all neocortical regions,
hippocampus, hypothalamus, brain stem nuclei (e.g., re-
ticular formation, inferior olivary and dentate nuclei)
and in Bergmann glia in cerebellum [56, 59]. The topo-
graphical distribution and frequency of intranuclear in-
clusions increase with age and length of the CGG repeat
segment, and also vary between brain regions [56, 59].
Pathology in the CGG KI mouse model differs from
FXTAS pathology by the absence of tremors and the
relatively few numbers of astrocytes with intranuclear in-
clusions [2]. Ubiquitin-positive inclusions were never
observed in neurons or astroglia of WT mice in any
brain region at any age [46].
To determine if expression of a CGG trinucleotide
repeat expansion in astroglia is sufficient to inducepathology in astroglia, and to characterize the role of
astroglia in FXTAS, we created a transgenic mouse line
(Gfa2-CGG99-eGFP) that expresses a 99 CGG repeat
expansion in astrocytes throughout the brain and in
Bergmann glia in the cerebellum. Expression is driven
by an astroglia-specific Gfa2 promoter fused to an
eGFP reporter gene. In these mice, immunocytochem-
ical analysis of eGFP expression patterns revealed that
CGG99-eGFP expression co-localized with astroglia
markers, but not with neuronal, microglia, or oligo-
dendroglia markers, indicating that CGG99-eGFP ex-
pression was specific for astroglia and Bergmann glia.
Double-immunostaining for ubiquitin revealed the
presence of intranuclear inclusions in eGFP-positive
glia throughout the brain, as well as ubiquitin-positive
inclusions in the cytoplasm of astrocyte processes. Sur-
prisingly, we also observed intranuclear inclusions in
NeuN-positive neurons of the hypothalamus and neocor-
tex, though these cells did not express the CGG99-eGFP
transcript. The presence of cytoplasmic inclusions in
astrocytes, ectopic inclusions and inclusions in neurons
suggests a spread of pathology from astrocytes to neurons
by as yet unknown mechanisms. Both glial and neuronal
inclusions stained positive for the RAN translation prod-
uct FMRpolyG [9, 52]. These results indicate that an ex-
panded CGG-99 repeat in astroglia is sufficient to induce
formation of ubiquitin- and FMRpolyG-positive intranuc-
lear inclusions - key features of FXTAS pathology, and
that the Gfa2-CGG99-eGFP mouse will be a valuable
model to delineate neuron-astroglia interactions that con-
tribute to FXTAS disease pathogenesis.
Materials and methods
Generation of Gfa2-CGG99-eGFP and Gfa2-CGG11-eGFP
mice
Transgenic mice on a C57BL/6j background were gener-
ated with an expanded CGG99 trinucleotide repeat
segment (Gfa2-CGG99-eGFP) or a typical mouse-sized
CGG11 (Gfa2-CGG11-eGFP) repeat sequence. For sim-
plicity, the Gfa2-CGG99-eGFP mice are referred to as
Gfa2-CGG99 and the Gfa2-CGG11-eGFP mice as Gfa2-
CGG11 control mice, respectively. Wildtype (WT) non-
transgenic littermates were generated from breeding the
Gfa2-CGG99 transgenic mice with WT C57BL/6j mice.
These WT littermates mice were used as controls for be-
havioral studies to avoid litter effects and because suffi-
cient numbers of the Gfa2-CGG11 transgenic mice were
not available. Genotype was verified in all mice by PCR
from tail-snips. A diagram of the DNA constructs and
the nucleotide sequences used for pronuclear injection
are shown in Fig. 1a and b, respectively. Expression vec-
tor maps are included in Additional file 1: Figure S1. Ex-
pression was restricted to astrocytes and Bergmann glia
using the astrocyte-specific Gfa2 promoter, with the
Fig. 1 a Diagram of DNA fragment used for pronuclear injection with either an 11CGG or 99CGG trinucleotide repeat expansion on exon 1. b
Nucleotide sequence of DNA construct used to make the GFAP-CGG11-EGFP or GFAP-CGG99-EGFP transgenic mice. The sequence contained
either an 11CGG or 99CGG trinucleotide repeat sequence for the two transgenic mouse lines that was located between the two arrows in b. The
bracketed acg sequence upstream of the repeat sequence shows the alternative translation start site supporting repeat-associated non-ATG (RAN)
translation as described in Sellier, et al., 2017
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used to identify cells expressing the Gfa2-CGG99-eGFP
or the normal length Gfa2-CGG11 transgene. The
eGFP sequence was derived from the pBR-eGFP vector.
Expression of the CGG99 and CGG11 trinucleotide
repeat expansions and eGFP reporter are driven by ~
2-kb of the human Gfa2 promoter, which drives astro-
cyte-specific expression in transgenic mice [5]. cDNA
derived from patient and control peripheral blood lym-
phocytes was used to isolate ~ 226 bp of FMR1 5′-UTR
sequence as well as the CGG repeats, which were
cloned into Blp I and Pst I restriction sites. The con-
struct also contains a chimeric intron upstream of
eGFP to enhance expression levels. Gfa2-CGG11-eGFP
and Gfa2-CGG99-eGFP clones (i.e., clones 3 and 11, re-
spectively) were digested with ApaLI and SnaBI (10 μgeach) and the respective 4.8 and 5.1 kb restriction
fragments were purified away from the 0.9 kb vector
backbone on an agarose gel. The purified Gfa2-CGG11-
eGFP (86 ng/ul & 1.8260/280 ratio) and Gfa2-CGG99-
eGFP (62 ng/ul & 1.8260/280 ratio) DNA fragments
were then microinjected into pronuclei of oocytes from
C57BL/6J x C3H/HeJ F1 hybrids at the University of
Washington Microinjection Service Laboratory. Six of
the 26 Gfa2-CGG11-eGFP mice screened (LS-2997,
LS-3006, LS-3009, LS-3011, LS-3025, LS-3030 were
found to be positive for the transgene by PCR. Six of
the 27 Gfa2-CGG99-EGFP mice screened (LS-3046,
LS-3049, LS-3060, LS-3061, LS-3065, LS-3072) were
also found to be positive for the transgene by PCR. The
Gfa2-CGG11 and Gfa2-CGG99 mouse lines used in
these experiments were selected based on matched,
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primers and probes to the eGFP gene as follows: for-
ward, 5′- GTC CGC CCT GAG CAA AGA -3′; reverse,
5′- TCC AGC AGG ACC ATG TGA TC -3′; Fam-
probe, 5′- CCC AAC GAG AAG CG -3′.
Eight male Gfa2-CGG99 mice and five male Gfa2-
CGG11 control mice between 4 and 16 months old
were used for histological and molecular studies. In
addition, brains of two male CGGn knock-in (CGG128
and CGG159) and 2 WT mice 16 months of age were
immunostained for ubiquitin-positive intranuclear in-
clusions in neurons and astroglia for comparison with
Gfa2-CGG99 mice and Gfa2-CGG11 mice, as previ-
ously described [56]. Transgenic and WT mice were
housed under conditions of constant temperature and a
12 / 12 h light-dark cycle, and with food and water ad
libitum. These experiments followed the “Principles of
laboratory animal care” (NIH publication No. 86–23,
revised 1985), and were approved by the UC Davis In-
stitutional Animal Care and Use Committee.Genotyping
DNA was extracted from mouse tails by incubating
with 10 mg/ml Proteinase K (Roche Diagnostics) in
300 μl lysis buffer containing 50 mM Tris-HCl, pH 7.5,
10 mM EDTA, 150 mM NaCl, 1% SDS overnight at 55 °
C. One hundred μl saturated NaCl was then added and
the suspension was centrifuged. One volume of 100%
ethanol was added, gently mixed, and the DNA was
pelleted by centrifugation and the supernatant dis-
carded. The DNA was washed and centrifuged in 500 μl
70% ethanol. The DNA was then dissolved in 100 μl
milliQ-H20. CGG repeat lengths were determined by
PCR using the Expanded High Fidelity Plus PCR Sys-
tem (Roche Diagnostics). Briefly, approximately 500–
700 ng of DNA was added to 50 μl of PCR mixture
containing 2.0 μM of each primer, 250 μM of each
dNTP (Invitrogen), 2% DMSO (Sigma), 2.5 M Betaine
(Sigma), 5 U Expand HF buffer with Mg (7.5 μM). For
the CGG KI mice the forward primer was 5′-GCTC
AGCTCCGTTTCGGTTTCACTTCCGGT-3′ and the
reverse primer was 5′-AGCCCCGCACTTCCACCAC
CAGCTCCTCCA-3′. For the Gfa2-CGG99 mice the
forward primer was 5′- GTC CGC CCT GAG CAA
AGA -3′; and the reverse primer was 5′- TCC AGC
AGG ACC ATG TGA TC -3.’ PCR steps were 10 min
denaturation at 95 °C, followed by 34 cycles of 1 min
denaturation at 95 °C, annealing for 1 min at 65 °C, and
elongation for 5 min at 75 °C to end each cycle. PCR
ended with a final elongation step of 10 min at 75 °C.
DNA CGG band sizes were determined by running
DNA samples on a 2.5% agarose gel and staining DNA
with ethidium bromide.Behavioral testing
The behavioral tests used in the present study for
GFAP-CGG99-EGFP mice were selected to examine
similar neurobehavioral deficits in FXTAS, including
anxiety in the elevated plus-maze, ataxia and motor
deficits in the ladder rung test, rotarod and TredScan
apparatus, and cognitive loss using contextual fear con-
ditioning [20].
Mice
Fifteen adult wildtype (WT) and 15 Gfa2-CGG99 adult
male mice were used for behavioral testing. The WT and
Gfa2-CGG99 mice were littermates derived from 12 lit-
ters with no more than 3 mice taken from any litter.
The mice were between 21 and 24 weeks of age at the
start of behavioral testing. WT littermates were used as
controls to avoid litter effects in behavioral testing, and
because sufficient numbers of Gfa2-CGG11 transgenic
mice were not available for the behavioral studies. Mice
were housed individually in a climate controlled vivar-
ium under 12:12 h light dark cycles with food and water
available ad libitum. Animals were tested in the order
presented below.
Open-field locomotor activity
Locomotor activity was measured using an automated
open-field activity arena (TruScan, Coulbourn Instr.,
Whitehall, PA). The apparatus (27.5 × 27.5 × 37.5 cm) de-
tects movement by recording infrared beam brakes. The
number of center entries, total time in the center and
periphery of the arena, and frequency of rearing were
automatically scored during a 90-min period.
Elevated plus maze
The maze consisted of two open arms (30 × 5 × 0.25 cm)
and two closed arms (30 × 5 × 6 cm) elevated 60 cm
above the floor. Mice were placed in the center of an el-
evated plus-maze and were allowed to freely explore the
apparatus for 5 min while recorded by a video-tracking
system (SMART, San Diego Instruments, San Diego,
CA). Number of entries into open and closed arms, la-
tency to first enter, and total time spent in open and
closed arms were compared between WT and Gfa2-
CGG99 mice.
Rotarod
Motor coordination and balance were evaluated using a
Rotamex-5 rotarod with photocell detection (Columbus
Instr., Columbus, OH). Prior to testing mice were given
an initial training session where they were acclimated
to the apparatus. Training consisted of a 120 s trial in
which the rod rotated at a constant speed of 4 RPM.
Mice that fell were immediately replaced and allowed
to complete the training session. Twenty-four hr. later
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at an initial speed of 4 RPM that accelerated by 1.0
RPM every 10 s. A trial was terminated when a mouse
fell from the rod at which time the speed and latency to
fall were recorded. The number of flips (i.e., 360 deg.
rotations while grasping the rod) was also recorded.
Each mouse was tested three times per day for three
consecutive days. Mean performance time per day was
defined as the average time the mouse remained on the
rotarod across trials.
Gait analysis
Gait abnormalities in Gfa2-CGG99 mice were analyzed
and compared to WT mice using a motor-driven trans-
parent treadmill affixed with high-speed digital video
camera and computer-assisted software (TreadScan,
CleverSys, Reston,VA). To ensure that all mice were
walking, and not galloping, the treadmill speed was ad-
justed for each mouse but never exceeded 20 cm/s.
When the mouse reached a steady gate, video of the
underside was recorded and analyzed by the system’s
software that identified each paw individually and cal-
culated gait variables. Variables included stride time,
defined as the time between two initial paw contacts of
the same paw, stance time, the period of time the paw
is in contact with the treadmill, and swing time, the
portion of the stride in which the paw is not in contact
with the treadmill.
Ladder rung task
The ladder rung apparatus tested visuomotor coordin-
ation by measuring the number of foot slips made
while traversing a horizontal ladder [31]. The apparatus
consisted of two 28 cm tall × 65 cm long black walls
separated by 10 cm. The floor was elevated 10 cm from
the bottom of the walls and had 43 parallel 1 mm diam-
eter bars separated by 1.5 cm. A video camera posi-
tioned at one end of the apparatus recorded the full
length of the beam floor. This allowed the experimenter
to score whether the mouse’s limbs extended below the
beam floor as well as allowed the experimenter to ob-
serve the general posture of the mouse above the beam
floor. All behavior was captured using a behavioral
tracking system (SMART, San Diego Instruments, San
Diego, CA). Mice were placed in the apparatus and
allowed to freely explore the apparatus for 2 min. Mice
typically explored the apparatus by walking the length
of the apparatus, looking over the edge, and returning
to the start position. The number of times a foot
slipped through the beam floor was recorded and used
as the dependent measure. Video recordings were later
independently scored by two experimenters blinded to
the genotype of the mice (intraclass correlation coeffi-
cient = 0.88, p < 0.002).Fear conditioning
Mice were trained in a contextual fear conditioning ap-
paratus (Med Associates Inc., Georgia, VT). Mice under-
went an initial training period consisting of 2 trials
separated by a 2 min inter-trial interval. Each trial con-
sisted of the presence of 80 dB white noise (conditioned
stimulus, CS) for 30 s which co-terminated with a 0.5
mA footshock (unconditioned stimulus, UCS) during
the last 2 s. The testing for contextual and cued fear
conditioning occurred 24 h later. For contextual condi-
tioning, the mice were returned to the training chamber
in the absence of the CS and UCS and measured for
freezing behavior during a five-minute period. For cued
fear conditioning, mice were placed in an altered context
chamber modified by new floor and side inserts. Mice
were measured for freezing during an initial 3-min
period and during a 3 min presentation of the CS. Freez-
ing was defined as the cessation of movement other than
respiration for ≥750 milliseconds.
Light microscopy/Electron microscopy/
immunocytochemistry
General tissue preparation
Histological procedures were previously described in
detail [56]. In brief, mice were anesthetized with so-
dium pentobarbital (100 mg/kg, i.p.), then perfused with
isotonic saline followed by a solution of 4% buffered
paraformaldehyde (PFA), and post-fixed in the same so-
lution for 1 h at 4 °C. The brains were cryoprotected in
buffered 10% sucrose for 1 h, followed by buffered 30%
sucrose for 24 h at 4 °C, then rapidly frozen on dry ice.
Thirty μm frozen sagittal sections were cut on a sliding
microtome, and collected into a series of every fifth
section in 30% sucrose. Single sets of sections were se-
lected for further processing that included: cresyl violet
and/or H&E staining for general histological evaluation,
electron microscopy to analyze the ultrastructure of
intranuclear inclusions in glia and neurons, immuno-
cytochemistry/immunofluorescence for neuronal and
glial cell markers, including ubiquitin staining used to
visualize intranuclear inclusions. These ubiquitin-
positive inclusions are the hallmark histopathology in
FXTAS patients and are also found in astrocytes and
neurons in CGG KI mice [23, 24, 59].
Immunocytochemistry
Immunocytochemical and immunofluorescence tech-
niques were used to visualize the occurrence and distri-
bution of intranuclear inclusions, specifically in brain
astroglia and cerebellar Bergmann glia of Gfa2-CGG99,
of Gfa2-CGG11 control and WT mice. Subsets of alter-
nate sections were processed for immunocytochemistry
using a modification of the avidin-biotin complex
(ABC)-peroxidase technique [29] as previously described
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(pH 7.4) and pretreated with 0.1% sodium borohydride
for antigen retrieval. Endogenous peroxidases were inac-
tivated by treatment with 0.5–2% H2O2. Sections were
then treated with 3% goat, horse and/or swine serum
(Sigma, St. Louis, MO; DAKO, Inc., Carpinteria, CA)
and 0.3% Triton X (TX) in 0.01M PB, 0.15M NaCl, pH
7.4 (PBS) for 1 h to reduce nonspecific staining. Follow-
ing rinses in PBS, sections were incubated for 48–72 h at
4o C in the primary antibodies: mouse monoclonal
anti-glial fibrillary acidic protein (GFAP), (DAKO, Inc.),
1:2000 (1:750 for immunofluorescence (IF); rabbit poly-
clonal anti-S100β (Abcam, Inc., Cambridge, MA),
1:1000; mouse monoclonal anti-myelin basic protein
(MBP), (Chemicon International, Inc., Temecula, CA),
1:500; mouse monoclonal anti-MAP 2 (Sigma), 1:2000
(1:1000 for IF); rabbit polyclonal anti-Iba1 (ionized cal-
cium binding adaptor molecule 1; Wako Chemicals
USA, Inc., Richmond, VA), 1:2000 (1:1000 for IF);
mouse-monoclonal anti-Kv2.1 (kindly provided by Dr.
J.S. Trimmer; UC Davis), 1:500 for IF; rabbit polyclonal
anti-eGFP (Invitrogen, A11122: 1:1000) and rabbit poly-
clonal antibody against ubiquitin (DAKO, Inc.), 1:2000,
(1:1000 for IF) in PBS containing 1% goat, horse or
swine serum, 2% BSA and 0.3% TX. Following rinses in
PBS, sections were incubated in biotinylated goat or
swine anti-rabbit IgG (DAKO, Inc.; Vector Laboratories,
Burlingame, CA), diluted 1:500 for 24 h at 4 °C. After
rinses in PBS, sections were incubated in ABC (Elite
ABC Kit, Vector Laboratories), diluted 1:500 in 2% BSA,
0.3% TX and PBS for 24 h at 4 °C. After rinses in PB
followed by Tris-HCl buffers (pH 7.4; 7.6), sections were
incubated in 0.025% 3,3′-diaminobenzidine (DAB,
Sigma) with 0.003% H2O2 in TB (pH 7.6). The incuba-
tion was stopped by rinses in TB and PB. For
double-immunostaining (e.g., GFAP/ubiquitin-colocali-
zation) differently-colored chromogens were used (DAB;
Vector SG Substrate Kits, Vector Laboratories). Specifi-
city of the immunostaining was evaluated by omitting
primary antibodies from the regular staining. Sections
were mounted on slides, dehydrated, cleared, and
cover-slipped with Permount.
Immunofluorescence staining
For single and multiplex immunofluorescent labeling of
ubiquitin and neuronal/glial cell markers, frozen sec-
tions were transferred into buffered 30% and/or 10%
sucrose, then rinsed in 0.1 M PB and treated with 0.1%
sodium borohydride for 15 min. Thereafter, sections
were rinsed again with 0.1 M PB and then perme-
abilized with 0.5% H2O2 in 0.1 M PB for 15 min
followed by rinses in 0.1 M PB and 0.01 M PBS.
Free-floating sections were treated with 10% goat
serum in 0.01M PBS containing 0.3% TX-100 (vehicle)for 1 h and then incubated overnight at 4 °C in vehicle
containing different combinations of mouse monoclo-
nal/rabbit polyclonal antibodies of different IgG
isotypes (see above). After rinses in 0.01 M PBS and
10% goat serum (vehicle), sections were incubated in
isotype-specific Alexa-conjugated secondary antibodies
(1:2000): Alexa 568- and/or 488-labeled goat anti-rabbit
IgG and/or Alexa 488 and/or 568-labeled goat anti-
mouse IgG (Invitrogen, Carlsbad, CA) for 1–2 h as
described previously [57]. Following rinses in vehicle,
sections were mounted on gelatin-coated slides and
cover-slipped with mounting medium containing DAPI
(4′, 6-diamidino-2-phenyindole di-lactate) for nuclear
staining (Vectashield “Hard Set”, Vector Laboratories).
Repeat-associated non-ATG (i.e., RAN translation)
translation of a novel potentially toxic peptide, FMRpo-
lyG, was recently described in the brains of CGG KI
mice [47]. Therefore we carried out immunostaining for
FMRpolyG in order to determine whether this peptide
was also present in the inclusions in the Gfa2-CGG99
mice. Whole Gfa2-CGG99 and WT mouse brains were
sectioned sagitally and the hemispheres were fixed over-
night in 4% paraformaldehyde and embedded in paraffin
according to standard protocols. Sections (6 μm) were
cut on a rotary microtome and deparaffinized, followed
by antigen retrieval using microwave treatment in 0.01
M sodium citrate. Endogenous peroxidase activity was
blocked and immunostaining was performed overnight
at 4 °C using mouse anti-GFP (Roche 181446011000),
rabbit anti-ubiquitin (Dako Z0458; 1:250), or mouse-anti
FMRpolyG (8FM) [9]; 1:10) antibodies. Antigen-antibody
complexes were visualized by incubation with DAB sub-
strate (Dako) after incubation with Brightvision poly-
HRP-linker (Immunologic). Slides were counterstained
with haematoxylin and mounted with Entellan.
Multiplex immunofluorescence staining for FMRpo-
lyG, ubiquitin, GFAP and NeuN were carried out in
separate brain sections. Sections were blocked for auto-
fluorescence with Sudan Black in 70% ethanol. Primary
antibodies included rabbit-anti ubiquitin (DAKO Z0458;
1:50), mouse-anti ubiquitin (Cytoskeleton AUB01-S;
1:200), mouse-anti FMRpolyG (1:10) [9], rabbit anti-
GFAP (Sigma G9269; 1:200), and mouse anti-Map 2
(Roche, 1:400). Secondary antibodies included anti-
rabbit Fab Alexa 488 (Life technologies A11070; 1:100)
and anti-mouse Cy3 (Jackson Immuno research 715–
165-150; 1:100). Nuclei were visualized with Hoechst.
Analysis was done with a Leica confocal microscope and
Leica Application Suite Advanced Fluorescence (LAS
AF) software (Leica Microsystems, Buffalo Grove, IL).
Electron microscopy
Frozen 30 μm brain sections were collected from CGG
KI and Gfa2-CGG99 transgenic mice perfused with 4%
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sucrose at 80 °C. Sets of sections were thawed and post-
fixed with Karnovsky fixation solution for 1 h. The sec-
tions were then postfixed with 1% buffered osmium
tetroxide for 1 h, then thoroughly rinsed with PB and
dehydrated in a series of ethanol solutions and flat em-
bedded in a mixture of Epon and Araldite between two
aclar sheets for 24 h at 70 °C as previously described
[55]. Serial ultrathin sections were collected on TEM
grids, and stained with uranyl acetate and lead citrate.
Sections were then examined in a Philips 120 electron
microscope. Electron microscopic images were acquired
digitally using a 2 k × 2 k high resolution CCD camera
(Gatan, Pleasanton, CA), and post-processed using
Photoshop software.
Cell identification and evaluation of Intranuclear
inclusions
The sections were analyzed using a Nikon ECLIPSE
E600 microscope with epifluorescence attachment and
digital camera. Images were converted to a file format
for processing as an Adobe Photoshop document. Im-
ages were analyzed to verify the presence of ubiquitin-
positive intranuclear inclusions in different cell types
identified with various neuronal and glial cell markers in
brains of Gfa2-CGG99, Gfa2-CGG11 and WT mice.
Cresyl violet and/or H&E-stained sets of brain sections
from transgenic and WT mice at different ages were
used for comparison and evaluation of gross anatomical
differences. The different cell types in the brain were de-
termined based on standard morphological criteria using
Nissl cell staining and neuronal and glial cell markers as
described previously [23, 56].
Neurons were identified by their size, large round nu-
clei, single or multiple nucleoli, and their abundant cyto-
plasm, as well as by using molecular neuronal markers
(e.g., NeuN, Kv2.1 channel protein). These descriptions
were confirmed using electron microscopy.
Astroglia were identified by their round/ovoid nuclei
with light euchromatin, and absence of nucleoli and
cytoplasm. In addition, GFAP- and S100β-immunocyto-
chemistry and/or immunofluorescence were used to
identify subpopulations of astroglia based on their differ-
ing immunoreactivities (i.e, protoplasmic and/or fibrous
astroglia) in different brain regions. These descriptions
were confirmed using electron microscopy.
Oligodendrocytes (MBP-immunopositive cells) were
identified based on their typical appearance with small,
round, hyperchromatic nuclei surrounded by thin som-
atic cytoplasm, and their localization to white and grey
matter.
Microglia were identified primarily on cellular morph-
ology obtained from Iba1 immunostaining which dis-
played small cell bodies with a round nucleus and fine,ramified processes that are characteristic of resting
microglia, and were clearly distinguishable from acti-
vated (but non-phagocytic) microglia and phagocytotic
cells (i.e., brain macrophages). For all cell types, im-
munocytochemical staining for ubiquitin was used to
specifically label intranuclear inclusions in combination
with cell-specific markers to identify the cell type (i.e.,
neuronal and/or non-neuronal cells). Finally, all cell and
inclusion types were determined and confirmed based
on their ultrastructural appearance and characteristic
features using electron microscopy.Laser capture/microdissection (LCM)
To evaluate the cellular specificity of Gfa2-CGG99-eGFP
expression, single cell laser capture microdissection
(LCM) was performed on ubiquitin-immunolabeled
cells. Gfa2-(CGG99)-eGFP, CGG knock-in (KI) and WT
mice were euthanized by lethal overdose with sodium
pentobarbital after which their brains were rapidly re-
moved and immediately frozen in OCT compound (Ted
Pella Inc., Redding, CA). Coronal sections were cut at
12 μm on a cryostat (Leica Microsystems Inc., Buffalo
Grove, Il). Sections were direct-mounted onto MMI
Membrane Slides (Molecular Machines & Industries
AG, Switzerland) and dried for 10 min at room
temperature. Sections were then rinsed briefly in water,
fixed in 70% ethanol for 1 min, and incubated in rabbit
polyclonal antibody against ubiquitin (DAKO, Inc.),
1:100 in 0.1 M PB with 5% goat serum for 1 h at room
temperature. After 3 brief washes in 0.1M PB, sections
were incubated in Alexa 488-labeled goat anti-rabbit
secondary IgG containing 5% goat serum for 1 h at room
temperature. Finally, sections were rinsed 3x briefly in
0.1M PB, counterstained with DAPI in 0.1 M PB for 1
min and dehydrated through a descending series of alco-
hols. After complete drying, slides were either directly
processed for LCM or stored at -80 °C.
LCM was performed on coronal sections using a
MMI CellCut Laser Capture Microscope (Molecular
Machines & Industries AG, Switzerland). Individual
neurons were captured onto isolation caps of specific-
ally designed centrifuge tubes (MMI) and maintained
frozen at -80 °C until RNA purification. Approximately
100–200 individual neurons containing ubiquitin-
positive inclusions, but negative for eGFP histofluores-
cence, were captured from 18 tissue sections from the
ventromedial hypothalamus and combined into a single
PCR tube. In addition, astrocytes expressing eGFP
fluorescence and bearing ubiquitin-positive inclusions
were laser-captured from 10 neocortical tissue samples
from Gfa2-CGG99-eGFP mice, combined and used as a
eGFP-positive control. For comparison 100–200 cells
from the amygdala of a CGG KI mouse with a CGG168
Fig. 2 Rotarod performance of Gfa2-CGG99 and WT mice. a Time to
fall from the rotarod was significantly longer for Gfa2-CGG99 versus
WT mice. In addition, Gfa2-CGG99 mice also showed significantly
more flips (number of flips shown in parentheses) than WT mice. b
The speed at which Gfa2-CGG99 mice fell from the rotarod was
significantly higher than WT mice. *p < 0.05, **p < 0.01
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bined as a negative control.
RNA isolation and amplification
Total RNA was isolated from LCM samples using a Qia-
gen RNeasy micro kit (Qiagen, Germantown, MD)
according to manufacturer’s recommendations. RNA
quantity and quality was estimated using a NanoDrop
spectrophotometer (ThermoFisher Scientific, Waltham,
MA) and Agilent Bioanalyzer (Agilent Techologies Inc.,
Santa Clara, CA). RNA from each sample was subjected
to linear amplification using Nugen Inc. SPIA technol-
ogy (Nugen Tehnologies Inc., San Carlos, CA). The
quantity and quality of resulting amplified cDNA was
assessed using a NanoDrop and Bioanalyzer.
Semi-quantitative real-time PCR
Real-time PCR was performed using an iCycler (Bio-
Rad) to measure incorporation of the fluorescent dye
SYBR Green I. For each reaction, a master mix of the
following was made: 1× PCR buffer (QIAGEN), 400 mM
dNTP, 0.5 mM forward (5′-AGTGGAGAGGGTGA
AGGTGA) and reverse (5′-GGTAAAAGGACAGGGC-
CATC) eGFP primers (Operon), 0.01× SYBR Green I
(Invitrogen), 1.5 mM MgCl2, 10 nM FITC (Bio-Rad), and
1 U of TaqDNA polymerase (QIAGEN). All PCRs were
optimal for the following cycle conditions, 94 °C (15 s),
60 °C (30 s), and 72 °C (30 s), and were run for approxi-
mately 40 cycles. After the PCR, a melting-curve analysis
was performed to confirm the specificity of the PCR. In
addition, samples of the PCRs were subjected to electro-
phoresis to verify product size and specificity. The rela-
tive quantification of RNA targets was performed as
follows: The threshold cycle (Ct) at which a gene of
interest first rose above background was determined and
subtracted from that of the housekeeping gene, β-actin,
the PCR for which was performed in a separate reaction
tube. This was termed ΔCt. The ΔCt for each reaction
was plotted as 2 −ΔCt. Therefore, all values are for RNA
expression normalized to β-actin mRNA.
Statistical analysis
Behavioral data were analyzed using R 2.14.0 language
and environment. Data for each variable were examined
for normality using the Shapiro-Wilk test and Kolmo-
gorovo-Smirnov test. Normally distributed data were
analyzed by Analysis of Covariance (ANCOVA) with
body weight as a covariate. If the assumption of normal-
ity of distribution was violated, then group comparisons
were carried out using nonparametric rank-based
ANCOVA with body weight as a covariate. The mini-
mum levels for statistical significance set at p < 0.05 for
all statistical analyses. Data in figures are means ± standard
error of the mean (SEM). Detailed statistical results forbehavioral experiments are provided in Additional file 1:
Figure S2.
Results
Gfa2-CGG99 transgenic mice exhibit neurological and
systemic disease phenotypes
Body weight
At 6months of age when behavioral testing began
Gfa2-CGG99 mice had significantly lower body weights
(31.1 ± 1.3 g) compared to WT (39.5 ± 1.3 g), and this
difference remained significant at 7 and 8months of age
(p < 0.01) (Additional file 1: Figure S2). Body weight was
therefore used as a covariate in statistical analyses. Body
length did not differ between Gfa2-CGG99 (93.6 ± 0.6
mm) and WT mice (94.9 ± 0.5 mm) at the start of behav-
ioral testing.
Rotarod
As shown in Fig. 2, Gfa2-CGG99 mice stayed on the
rotarod significantly longer (e.g., A. Time to Fall) than
WT mice on trials 2, 3, 4, 6 & 9, but not on trial 1. A
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significantly longer for Gfa2 compared to WT on trials
2, 3, 4, & 9 (p < 0.05). Numbers in parenthesis in Fig. 2a
show that Gfa2-CGG99 mice flipped (i.e., clinging to
the rotarod cylinder through complete 360 deg. rota-
tions) on 8 of 9 trials compared to only 3 of 9 trials for
WT (p < 0.05). Eleven of 15 Gfa2 mice showed one or
more episodes of flipping compared to 2 of 15 WT
mice (p < 0.01).
Gait analysis
Gfa2-CGG99 mice differed from WT mice in several
basic gait parameters measured in the TredScan appar-
atus (Fig. 3). Gfa2-CGG99 mice had shorter stance times
(time in contact with floor) for front-left and rear-right
feet compared to wild type controls (p < 0.05). Maximum
longitudinal deviation was significantly shorter in
Gfa2-CGG99 mice compared to WT for the front-left (p
< 0.05), front-right (p < 0.05) and rear-right (p < 0.05), in-
dicating a shortened range of motion for the Gfa2-
CGG99 versus WT mice. No other significant gaitFig. 3 Gait analysis. A. maximum longitudinal deviation was
significantly shorter for the right and left front and left rear feet of
Gfa2-CGG99 mice compared to WT mice. B. Stance time was
significantly shorter for Gfa2-CGG99 compared to WT mice for the
left front and right rear feet. Mice were tested at 7 months of age; n
= 15 per group. *p < 0.05, **p < 0.01differences were found between genotypes for any other
measure. When adjusted for body weight differences
these gait effects were no longer statistically significant.
Ladder rung test
Gfa2-CGG99 mice made significantly more foot slips
while crossing the ladder run apparatus compared to
WT controls (Fig. 4). A one way ANCOVA with body
weight and locomotor activity as covariates showed that
this difference between groups was statistically signifi-
cant (p < 0.001).
Anxiety tests
No statistically significant differences in measures of
anxiety were found between Gfa2-CGG99 and WT mice
in the elevated plus-maze (time in open arm) or open
field tests (margin time). Interestingly, Gfa2-CGG99
mice showed an increased frequency of rearing behav-
iors compared WT mice (p < 0.05).
Contextual fear conditioning
No differences were found between WT and Gfa2-CGG99
mice for either contextual or cued fear conditioning.
Intranuclear inclusions in neurons and astroglia in CGG
Knock-in (KI) mice
Ubiquitin-positive intranuclear inclusions are the
hallmark neuropathology in FXTAS patients [26, 27],
and similar appearing inclusions are found in a CGG
knock-in (KI) mouse model of the fragile X premutation
[61, 64]. Figure 5 shows representative red immunofluor-
escent staining for ubiquitin-positive intranuclear inclu-
sions in neurons (arrowheads) and in a astrocytes
(arrow). Astrocyte was labeled immunofluorescent green
for GFAP. Brain section is from layer I of the parietal
cortex of a 16 month old CGG KI mouse with a 128
CGG trinucleotide repeat expansion. Ubiquitin-positive
inclusions were never observed in neurons or astroglia
of WT mice used in this study, or in our previous stud-
ies in any brain region at any age [46].
Expression pattern of eGFP in astroglia of Gfa2-CGG99
and Gfa2-CGG11 mice (Fig. 6)
As expected, astrocytes showed green eGFP histofluores-
cence through the brain in Gfa2-CGG99-eGFP (Fig. 6a)
and Gfa2-CGG11-eGFP (Fig. 6b) mice. This is shown for
the rostral neocortex where eGFP expression was higher
in Gfa2-CGG99 (Fig. 6a) compared to Gfa2-CGG11
mice (Fig. 6b). Gfa2-CGG99 mice showed eGFP histo-
fluorescence in the majority of astroglia across all brain
regions (e.g., neocortex, hippocampus, cerebellum, brain
stem nuclei). High levels of eGFP histofluorescence were
seen in somata, as well as the larger processes and
majority of fine processes which appeared as a “green-
Fig. 4 Gfa2-CGG99 mice made significantly more foot slips than WT mice in the ladder rung task. Mice were tested at 8 months of age; n = 15
per group. **p < 0.01
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and g). Immuno-labeling astrocytes with GFAP, micro-
glia with Iba1 and neurons with NeuN or MAP 2 was
carried out to determine specificity of expression of
eGFP in the different cell types. The results revealed that
eGFP histofluorescence was only observed in astrocytes
and Bergmann glia, and not in microglia, oligodendro-
glia or neurons.
Gfa2-CGG99 mice display nuclear pathology in astroglia
Although greater than 50% of astroglia in the Gfa2-
CGG99 mice expressed eGFP, ubiquitin-positive inclu-
sions were only observed in 0.1–0.5% of predominantly
protoplasmic astroglia, depending on age and brainFig. 5 Immunofluorescent labeling and ultrastructure of ubiquitin-
positive intranuclear inclusions in neurons and astroglia of the CGG
KI mouse. Ubiquitin-positive intranuclear inclusions (red) in a
protoplasmic astroglia (green; arrow) and pyramidal neurons (arrow
heads) in the neocortex of a CGG128 KI mouse. These fluorescently
labeled intranuclear inclusions are shown for comparison with
inclusions found in astrocytes in the Gfa2-CGG99 mouse brain.
Ubiquitin was immunofluorescently labeled red, GFAP green, and
nuclei stained blue using DAPIregion examined. Astrocytes with inclusions, although
low in number, were widely distributed throughout the
brain including neocortex, cerebellum and occasionally
in subcortical brain regions (e.g., hypothalamus and
some brain stem nuclei). Figs. 6c-d show astroglia visual-
ized by eGFP histofluorescence (6C) or co-labeled for
the glial marker GFAP (6D) with ubiquitin positive intra-
nuclear inclusions (arrows). The inclusions were spher-
ical bodies averaging 1.82 ± 0.29 μm in diameter located
within DAPI-stained nuclei of astroglia (Figs. 6c-d). No
ubiquitin-positive intranuclear inclusions were found in
astrocytes from WT mice (e.g., Fig. 6e) identified by
anti-GFAP immunofluorescence, or in the Gfa2-CGG11
transgenic control mice (e.g., Fig. 6f ). Examples of a
Gfa2-CGG99 neocortical astrocyte lacking or harboring
a ubiquitin-positive intranuclear inclusion are shown in
Fig. 6g and h, respectively. Interestingly, eGFP expression
appeared to be lower in astrocytes from Gfa2-CGG99
mice that contained ubiquitin-positive intranuclear inclu-
sions. For example, compare eGFP histofluorescence in an
astrocyte without an inclusion in 6G to an astrocyte with
an inclusion in 6H. Developmentally, intranuclear
ubiquitin-positive inclusions in astroglia were first ob-
served in neocortex at 4months of age, but the number
was low and only increased slightly at older age (greater
than 10months). We did not find evidence of increased
astrocyte proliferation (i.e., gliosis) in the Gfa2-CGG99 or
Gfa2-CGG11 mice.
Gfa2-CGG99 mice exhibit intranuclear inclusions in
Bergmann glia
Glia with characteristic Bergmann cell morphology [7,
32, 42, 56, 59] were observed by eGFP histofluorescence
Fig. 6 (See legend on next page.)
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Fig. 6 Intranuclear inclusions in neocortical astrocytes and Bergmann glia in Gfa2-CGG99 mice. a-b EGFP histofluorescence (green) in neocortical
astrocytes from a (a) Gfa2-CGG99, and a (b) Gfa2-CGG11 transgenic mouse. The majority of astrocytes in the Gfa2-CGG99 mouse cortex expressed
eGFP, while fewer astrocytes showed expression in the Gfa2-CGG11 mouse. Sections were immunoreacted against ubiquitin (red) and nuclei
stained with DAPI (blue). Red/yellow fluorescent puncta are due to autofluorescence of lipofuscin granules in neurons and microglia associated
with normal aging in the mouse cortex. Scale bars: 50 μm. c-d Intranuclear inclusion (c) in an eGFP histofluorescent Gfa2-CGG99 mouse astrocyte
immunostained for ubiquitin (arrow, orange/yellow). d Ubiquitin-stained intranuclear inclusion (arrow, cyan) in a Gfa2-CGG99 astrocyte verified as
an astrocyte by staining with anti-GFAP (red fluorescence). Scale bars: 5 μm. e-h Typically appearing protoplasmic astrocyte from a WT mouse
immunostained for Gfap (e, green). Shown for comparison with histofluorescent (green) Gfa2-CGG99 astrocytes in f-h). f Green histofluorescence
in an astrocyte from a Gfa2-CGG11 transgenic mouse, and from a (g) Gfa2-CGG99 transgenic mouse. Both show a cloud-like histofluorescence
emanating from their astrocytic processes, and neither contained a ubiquitin-positive intranuclear inclusion. h Intranuclear inclusion (arrow,
yellow) in a green histofluorescence astrocyte from a Gfa2-CGG99 mouse. Although not quantified, astrocytes in Gfa2-CGG99 mice with inclusions
appeared to show less green eGFP histofluorescence compared to astrocytes without inclusions (e.g., compare green histofluorescence in g and
h). Scale bars 10 μm. I-L EGFP histofluorescence (green) in cerebellar Bergmann glia from a Gfa2-CGG11 (i) and Gfa2-CGG99 (j) transgenic mouse.
In panel, i note the green histofluorescence in the soma and radial glial processes of the Bergmann glia in the Gfa2-CGG11 mouse (small arrows).
Ubiquitin-stained intranuclear inclusions (arrows, red fluorescence) in Bergmann glia (Figs. j and l, arrows) and in a protoplasmic astroglia in the
granule cell layer of the cerebellum (Fig. 6k, arrow) from a Gfa2-CGG99 mouse. Microglia immunolabeled with Iba1 (red fluorescence) did not
show eGFP histofluorescence and did not have ubiquitin-stained intranuclear inclusions (l, small arrow). Scale bars 10 μm. Figs. a-c,e-l
immunostained ubiquitin visualized with Alexa 568 2o antibody (red). Fig. d, immunostained ubiquitin visualized with Alexa 488 fluorescent 2o
antibody (green), astrocytes immunostained for GFAP and visualized with Alexa 568 (red). Fig. e, astrocyte immunostained for GFAP and
visualized with Alexa 488 (green). Fig. L, microglia immunostained for Iba1 and visualized with Alexa 568 (red). Figs. a-l nuclei stained with
DAPI (blue)
Fig. 7 a-c: Ubiquitin-positive intranuclear inclusions were unexpectedly found in neurons. Neuronal intranuclear inclusions are shown for the
paraventricular nucleus (a) of the hypothalamus (arrowheads in a; brown DAB reaction product) and ventromedial hypothalamus (arrowheads in b). No
inclusions were found in neurons in Gfa2-CGG11 control mice (c) or in WT mice. d-f: Immunohistofluorescent staining for ubiquitin-positive intranuclear
inclusions (arrowhead) in neurons in Gfa2-CGG99 mice in the inferior olivary nucleus (d) and suprachiasmatic nucleus (e). f For comparison, these
inclusions are similar to the inclusions found in neurons in the mammillary body of a CGG159 KI mouse. In Figs. d-f, ubiquitin is immunofluorescently
labeled green (Alexa 488, arrowheads) and neurons identified by immunostaining red for NeuN (Alexa 468). Scale bars: a-c: 5 μm; A-F: 10 μm
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CGG11 mice. Figure 6i shows a representative example
of a Bergmann glia cell from a Gfa2-CGG11 transgenic
mouse which has the characteristic morphology of Berg-
man glia (small arrows point to radial processes). No
ubiquitin-positive inclusions were found in Bergmann
glia from Gfa2-CGG11 mice. In contrast, ubiquitin-
positive intranuclear inclusions averaging 1.88 ± 0.36 μm
in diameter were observed in somata of Bergmann glia
from Gfa2-CGG99 mice (Figs. 6j, k, l, arrows). It is not-
able that ubiquitin-positive inclusions were more fre-
quently found in Bergmann glia of the cerebellar lobuli
1, 2 and 10, and rarely in the other lobules. All of the
ubiquitin-positive inclusions associated with Bergmann
glia had defined spherical structures and were located
within DAPI-positive nuclei. In addition to Bergmann
glia, ubiquitin-positive inclusions were also seen in the
velate protoplasmic astroglia of the granule layer, and in
astroglia located within the molecular layer and white
matter of the cerebellum (not shown). Ubiquitin-positive
inclusions were not found in nuclei of Purkinje cells or
other cerebellar neurons in Gfa2-CGG99 mice or from
Gfa2-CGG11 control mice. We also did not observe a
pattern of Purkinje cell loss in Gfa2-CGG99 mice resem-
bling that reported earlier in transgenic mice expressing
a similar, but not identical construct [47]. Further, there
were no ubiquitin-positive inclusions identified in select-
ively stained oligodendroglia (not shown) or in microglia
(an Iba1-labeled red fluorescent microglia without an in-
clusion is shown in the bottom right of panel 6 L, small
arrow; larger arrow points to an inclusion in an adjacent
Bergmann glia).
Neuronal intranuclear inclusions were found in Gfa2-
CGG99 mice
Neuronal intranuclear inclusions are key pathological
features of CGG KI mice that appear as early as 3
months of age [7, 32, 56, 59]. We did not see and did
not expect to see intranuclear inclusions in Gfa2-
CGG11 control mice because we were using the Gfa2-
specific promoter to limit expression to glia (e.g., Fig. 7c).
Unexpectedly, all of the Gfa2-CGG99 mice studied ex-
hibited some ubiquitin-positive inclusions in neuronal
nuclei in distinct brain regions, particularly in the hypo-
thalamus, including the paraventricular (Fig. 7a) and
ventromedial (Fig. 7b) nuclei. In contrast to these re-
gions, neuronal inclusions in Gfa2-CGG99 mice, al-
though present, occurred less frequently in neocortex
and cerebellum. Intranuclear inclusions were particularly
large in periventricular nuclei (Fig. 7a). Neuronal intra-
nuclear inclusions were also found in brainstem nuclei
(e.g., substantia nigra, reticular formation; data not
shown). The appearance of neuronal inclusions in Gfa2-
CGG99 mice was age-dependent, with 4–8 month oldmice exhibiting only a few neuronal intranuclear inclu-
sions, while older mice displayed higher numbers of
inclusions in the brain regions described above. The
presence of intranuclear ubiquitin-positive inclusions in
neurons was further established by showing co-
localization of the inclusions in cells that were identified
as neurons by immunofluorescence for well-accepted
neuronal markers, including NeuN (Figs. 7d & e, arrow-
heads), and showing localization within nuclei by DAPI
staining. The inclusions showed a similar appearance to
those previously described in neurons in the CGG KI
mouse (Fig. 7f ) [56].
In order to determine whether inclusion formation
could be related to “leaky” expression in neurons of the
astrocyte-specific Gfa2 promoter in Gfa2-CGG99 mice,
brain sections were immunoreacted using multiple
antisera for NeuN, GFAP, and/or eGFP. These experi-
ments revealed that (i) ubiquitin-positive inclusions were
present in neurons, in addition to astroglia, in various
brain regions; (ii) NeuN-positive cells (i.e., neurons) did
not show any detectable eGFP histofluorescence and/or
GFAP immunoreactivity in the nucleus or cytoplasm;
and (iii) only astroglia expressing eGFP (not neurons)
were immuno-positive when reacted with antiserum
against eGFP and GFAP.
Absence of eGFP expression in neurons with inclusions
analyzed by single cell, laser-capture microdissection
(LCM) PCR: Possible evidence for transfer of pathology
from astrocytes to neurons
The unexpected finding that neurons without eGFP
histofluorescence had inclusions suggested the possibil-
ity of cell-to-cell transfer of pathology from astrocytes
to neurons in Gfa2-CGG99-eGFP mice. However, it is
also possible that eGFP expression in neurons was
below the level of detection by histofluorescence. To
test this possibility, PCR analysis of laser-capture mi-
crodissected cells (LCM) was used to detect possible
eGFP mRNA expression in inclusion-bearing neurons
in the ventromedial hypothalamus (VMH) of Gfa2-
CGG99 mice, a region with numerous neuronal inclu-
sions (e.g., see Fig. 7b). Specifically, neurons in the
VMH that lacked eGFP histofluorescence but contained
ubiquitin-positive intranuclear inclusions were identi-
fied by immunofluoresent staining (Figs. 8a1 & a2), iso-
lated by LCM (Fig. 8a3) and combined for PCR analysis
(Fig. 8b & c). Total RNA was isolated, quantified and
linearly amplified using NuGEN SPIA technology
(www.nugen.com). The resulting cDNA was processed
for semi-quantitative real-time PCR with primers spe-
cific for EGFP and β-actin. As a positive control, RNA
was also isolated from regions of neocortex that
included astroglia that expressed eGFP (i.e., GFA2
cortex). In addition, we isolated single cells with
Fig. 8 Ventromedial hypothalamic neurons with inclusions from Gfa2-CGG99 mice do not express eGFP by qPCR analysis. A1–3: (a1) Neurons in
ventromedial hypothalamus (VMH) containing ubiquitin positive inclusions were visualized in 14 μm cryosections of brain by immunofluorescent
labeling (green immunofluorescence). (a2) Same section with DAPI staining. (A3) Neurons with inclusions were collected by laser capture
microdissection (LCM). b Total RNA was extracted and amplified from LCM neurons and qPCR analysis was performed to detect expression of
eGFP. VMH neurons from Gfa2-CGG99 mice with inclusions did not show detectable expression of eGFP (GFA2 LCM Neurons). In contrast, eGFP
expression was readily detected in large LCM samples from cerebral cortex that included astrocytes with eGFP expression (GFA2 Cortex). H2O was
a water control. As an additional tissue control, single neurons from the amygdala of a CGG KI mouse (168 CGG repeats) were isolated by LCM
and analyzed for eGFP expression (CGG KI Amygdala), and as expected since these mice do not carry the eGFP reporter gene, no expression was
detected. Red dashed line shows the detection threshold for qPCR analysis. c Analysis of qPCR samples by gel electrophoresis confirmed
amplification of eGFP in cortical samples containing eGFP positive astrocytes, but not in samples of LCM-isolated hypothalamic neurons. L, DNA
ladder; 1, CGG KI amygdala; 2, GFA2 LCM neurons; 3, GFA2 cortex; 4, water; 5, eGFP and/Actin positive plasmid controls. Scale bar = 50 μm
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(i.e., CGG KI Amygdala) that should not express eGFP.
These neurons express an expanded CGG repeat under
the control of an endogenous Fmr1 promoter, develop
neuronal intranuclear inclusions but do not express
eGFP [3, 18, 56]. We did not observe expression of eGFP
mRNA in VMH neurons with ubiquitin-positive intranuc-
lear inclusions (GFA2 LCM Neurons; Fig. 8b). Similarly,
neurons isolated from the amygdala of a CGG168 KI
mouse did not express eGFP (Fig. 8b). In contrast, larger
cortical samples from Gfa2-CGG99 mice expressed high
levels of eGFP mRNA (Fig. 8b) reflecting the presence of
astroglia expressing the eGFP protein. The expected size
and relative purity of PCR reactions were confirmed by
gel electrophoresis (Fig. 8c).Intracytoplasmic inclusions in astroglia of Gfa2-CGG99 mice
Ubiquitin-positive inclusion bodies in Gfa2-CGG99
mice did not appear to be restricted to the nuclear
compartment (Fig. 9). Initial observations in brain sec-
tions from Gfa2-CGG99 mice stained with neutral red
and immunostained for ubiquitin revealed inclusion
bodies that did not appear to be closely associated with
somata of astrocytes or neurons. These ectopic inclu-
sion bodies shown in Fig. 9a were prevalent across grey
and white matter of all brain regions examined, but
particularly frequent in upper neocortical layers, hippo-
campus, olfactory bulb and certain brain stem nuclei.
These bodies (aggregates) were spherical and averaged
3.62 ± 1.26 μm in diameter. In some regions (e.g.,
ventromedial hypothalamus) they appeared to form
Fig. 9 Ectopic and intracytoplasmic ubiquitin-positive inclusions in Gfa2-CGG99-eGFP expressing astroglia. a Ubiquitin-positive astrocyte intranuclear
inclusion (small arrow) and nearby inclusions that appear to be extracellular (arrowheads) in a neutral-red stained section of hilus from a Gfa2-CGG99
mouse. Insert a: Intranuclear (small arrow) and extracellular (arrowhead) ubiquitin-positive inclusions. DAB immuno-peroxidase staining was used to label
ubiquitin-positive inclusions in A and inset a. b Intracytoplasmic ubiquitin-positive inclusion (arrowhead) in an eGFP histofluorescent astrocyte in the
stratum oriens of hippocampal CA1 region; pcl pyramidal cell layer. Inset b shows higher magnification of the inclusion body (arrowhead). c An eGFP
histofluorescent astrocyte from a Gfa2-CGG99 mouse with an intracytoplasmic ubiquitin-positive inclusion body (arrowhead) within the hippocampal
CA1 stratum radiatum. d Ubiquitin-positive intracytoplasmic inclusion (arrowhead, yellowish-green fluorescence) that co-localizes with eGFP in the CA1
pyramidal cell layer (d). Inclusions were immunolabeled eGFP (red) and ubiquitin (green), so that co-localization with the inclusions appears as yellowish-
green fluorescence. Note that eGFP histofluorescence from expression of the eGFP reporter gene (green) is also present. Nuclei were labeled with DAPI.
d-f Co-localization of intracytoplasmic inclusions (arrowheads) in astrocytes immunofluorescently labeled with ubiquitin (green) and GFAP (red). eGFP
histofluorescence from expression of the eGFP reporter gene (green) is also present. Nuclei were labeled with DAPI. Scale bars: a-f: 10 μm
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sitive for ubiquitin (dark-blue reaction product) using
DAB peroxidase reaction (inset 9a), and/or exhibited
ubiquitin immunofluorescence (arrowheads, Fig. 9b-f ).
Some appeared to be engulfed or surrounded by fine
astroglial processes suggesting the inclusion bodies
were intracytoplasmic in astroglia (Figs. 9b-c, inset b;
arrowheads). Co-localization of inclusions with eGFP
(Fig. 9d & e) and GFAP (Fig. 9f ) confirmed the associ-
ation of these inclusions with astrocytes. This observa-
tion was confirmed by electron microscopy (EM) as
described below (Figs. 11i & k).
The RAN translation product FMRpolyG is present in
inclusions found in the Gfa2-CGG99 mice
Figure 10a shows an FMRpolyG-positive (red fluores-
cent) intranuclear inclusion in a GFAP-positive (green)
neocortical astroglia from Gfa2-CGG99 mouse (arrow).
This observation provides the first evidence for RAN
translation in astroglia in a mouse model of the FXTAS.
In addition, FMRpolyG immunostaining was also seen
in an inclusion body in MAP 2-positive (green) neuronin the hypothalamus (arrow, Fig. 10b). Arrowheads in
10A and 10B, show FMRpolyG-positive inclusions that
are likely in an unlabeled neuron and an unlabeled
astrocyte, respectively. Combined with the evidence
against eGFP transgene expression in neurons (i.e., Fig.
8; laser-microdissection single-cell PCR for eGFP), the
finding of FMRpolyG in neurons suggests that some
form of cell-to-cell transfer of pathology, possibly in-
volving FMRpolyG, may occur in Gfa2-CGG99 mouse
brains. This could be similar to a recent report of
cell-to-cell transfer of RAN translation peptides in
other models of trinucleotide (or hexanucleotide) re-
peat disorders [58].
Electron microscopy (EM) of inclusion bodies in astrocytes
and neurons
Neurons and astroglia of CGG KI mice)
Figure 11a and b (higher magnification) show electron
micrographs of inclusions in the nucleus of neocortical
pyramidal neurons from a CGG159 KI mouse. Figs. 11c
& 11d (higher magnification) show inclusions in the
nucleus of an astroglia in the neocortex from the same
Fig. 10 Double immunofluorescent staining reveals FMRpolyG positive inclusion bodies in both astrocytes (a) and neurons (b) from Gfa2-CGG99
mice. a. Photomicrograph showing FMRpolyG-positive inclusion bodies (red) located within GFAP positive astrocytes (green; arrow) as well as in a
GFAP negative cell that is probably neuronal (arrow head). b. Photomicrograph showing FMRpolyG-positive inclusion bodies (red) located within
a MAP 2 positive (green; arrow) neuron as well as in a MAP 2 negative cell that is probably an astrocyte (arrow head). c Representative brain
section from a Gfa2-CGG99 mouse processed for immunofluorescence but without 8FM mouse anti-FMRpolyG primary antibody
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ultrastructural features of a nucleolus (single asterisks)
in which the partes granulosa and fibrosa appear as
clearly separated regions and in which filaments and/or
granules are dominant (Peters et al., 1987). In contrast,
inclusions in neurons (double asterisks) appear as
compact, non-membrane bound arrangements of more
loosely packed ribosome-like granules and fine fila-
ments. Inclusions in CGG KI mice range between 1 and
2.5 μm dia, similar to that reported earlier for immuno-
stained neuronal intranuclear inclusions [56]. Intranuc-
lear inclusions were mostly located closely to the
nucleolus and varied in size. Occasionally some neu-
rons contained 2 intranuclear inclusions.
Inclusions in astrocytes of Gfa2-CGG99 mice
As shown in Fig. 11e and f (higher magnification), intra-
nuclear ubiquitin-positive inclusions in astroglia
appeared as a compact collection of densely packed
granulo-filamentous material often closely localized to
the marginal chromatin of the nucleus.
Inclusions in neurons of Gfa2-CGG99 mice
Figured 11G and 11H (higher magnification) show a rep-
resentative example of a nucleolus (single asterisk) and
proximal intranuclear inclusion (double asterisk) in a
neuron in the posterior hypothalamus of a Gfa2-CGG99
mouse. The overall appearance of these inclusions was
similar to that seen in the CGG KI mouse described
above (compare with Fig. 11a). As shown at high magni-
fication in 11H, inclusions in neurons appeared ascompact arrangements of non-membrane bound
granulo-filamentous material consisting of densely-
packed ribosome-like granules and filaments. Intranuc-
lear inclusions were mostly located closely to the
nucleolus and varied in size and shape.
Cytoplasmic inclusions in astrocytes
Electron microscopic examination revealed that these
apparently non-membrane bound inclusion bodies are
intracellular and surrounded by cytoplasm of astroglia
processes containing mitochondria, ribosomes/poly-
somes and intermediate filaments, a characteristic fea-
ture of astroglia (Figs. 11i,j and k,l). Some cytoplasmic
inclusion bodies contained an electron dense central re-
gion (core) exhibiting an amorphous to granular charac-
ter. This core is surrounded by a less dense peripheral
region (rim), in which predominantly loosely packed
filaments are present, oriented in linear/radial direction.
The adjacent cytoplasm often contained bundles of
intermediate filaments and mitochondria. The size and
morphology of these inclusions is similar in to the intra-
nuclear neuronal inclusions of FXTAS patients observed
by EM in human hippocampus [24] and in dorsal root
ganglion cells [22].
Discussion
Solitary intranuclear ubiquitin-positive inclusions in
neurons and astroglia are the hallmark neuropathology
in FXTAS [23, 24]. CGG KI mice used to model FXTAS
have similar intranuclear inclusions in both neurons
and astroglia [3, 6, 56]. The present study focused on
Fig. 11 a Electron micrographs of two layer 3 pyramidal neurons in
the neocortex from a 15.5 month-old CGG159 KI mouse (159 repeats)
showing the nucleoli (asterisk) and intranuclear inclusions (double
asterisks) in each of the nuclei (nu). Inset “a” shows the nucleolus
(asterisk) and a non-membrane bound electron-dense inclusion
(double asterisks) of the left neuron. b Higher magnification of the
adjacent region between the nucleolus (single asterisk) and
intranuclear inclusion (double asterisks) from inset “a”. Note the
granulo-filamentous ultrastructure of the inclusion material. c Electron
micrograph of a protoplasmic astroglia in the neocortex of the same
CGG KI mouse showing the marginal localization of the
heterochromatin (arrowheads) and an intranuclear inclusion (arrow)
within the nucleus (nu). d The inclusion in C shown at higher
magnification consists of a predominantly granular material (double
asterisks) surrounding some chromatin-like dense material (single
asterisk) within the center. Scale bars: a, 10 μm; b, 1 μm; b, 5 μm; c, e,
0.2 μm; d, 2 μm. e Electron micrograph of a fibrous astroglia in the
posterior hypothalamus of a Gfa2-CGG99 mouse with an intranuclear
inclusion (double asterisk) within the nucleus (nu). Note the marginal
chromatin localization (arrowheads) in the nucleus. f Higher
magnification of the intranuclear inclusion (double asterisk) reveals an
electron-dense structure inclusion body made up of predominantly
granular material and filaments (small arrow). Scale bars: M 1 μm; N
0.2 μm. g Electron micrograph of a principal neuron in the posterior
hypothalamus of a Gfa2-CGG99 mouse that shows the nucleolus
(single asterisk) and an intranuclear inclusion (double asterisks) within
the nucleus (nu). h Higher magnification of the adjacent regions of the
nucleolus (single asterisk) and the intranuclear inclusion (double
asterisk) in g which exhibit different ultrastructural features of the
granular-filamentous material in the nucleolus versus the inclusion.
Note the higher electron density of the nucleolus (pars granulosa and
fibrosa) as compared with the more uniform appearing inclusion
material. Scale bars: g: 2 μm; h: 0.2 μm. i Electron micrographs of
intracytoplasmic inclusion body located within astrocytic processes in
the posterior hypothalamus of a Gfa2-CGG99 mouse. The inclusions
display an electron-dense core (double asterisks) and a lighter rim
(single asterisk) which varied in size between inclusions (compare with
inset i). Note the intermediate filaments within the cytoplasm (if) near
the inclusion. j Higher magnification of the inclusion body in I presents
an amorphous to granular material within the core and a granular-
filamentous material within the rim. Note the intermediate filaments
(if) - a characteristic feature of the astrocytic cytoplasm. k
Intracytoplasmic inclusion body in the posterior hypothalamus exhibits
a large electron-dense core surrounded by a thinner and less dense
rim region. Note the mitochondria (M) in the adjacent cytoplasm of
the astrocytic process. l Higher magnification of a portion from the
inclusion body shows a linear-oriented filamentous material in the rim
(asterisk) and a dense granular-filamentous material in the outer zone
of the core (small arrows). Scale bars: i, i, 1 μm; k, 1 μm; j, l, 0.2 μm
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FXTAS that selectively expressed a CGG99 trinucleotide
repeat expansion fused to eGFP in astroglia and Berg-
mann glia (the Gfa2-CGG99 mouse). These investigations
revealed that: (i) strong eGFP fluorescence in astrocytes
and Bergmann glia was widespread throughout the brain
with some glial cells exhibiting ubiquitin-positive inclu-
sions; (ii) subsets of neurons located within the brain and
brainstem (e.g., hypothalamus, reticular formation, olivary
nuclei) also developed intranuclear ubiquitin-positive
inclusions; (iii) intracytoplasmic inclusion bodies were
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cesses; (iv) inclusion bodies in astrocytes and neurons
immunolabeled for the RAN translation product FMRpo-
lyG; and (v) Gfa2-CGG99 mice showed primarily a motor
deficit phenotype. The rationale for developing transgenic
Gfa2-CGG99-eGFP mice was to create a mouse model to
determine the role of astroglia in overall FXTAS path-
ology. To this end, the Gfa2-CGG99 mice provide evi-
dence that pathology mainly restricted to astrocytes can
contribute to abnormal motor function, as seen on the
ladder rung test, analysis of gait and rotarod performance
compared to WT controls. However, the fact that intra-
nuclear inclusions were also found in neurons in the
Gfa2-CGG99 mice complicates attempts to attribute spe-
cific pathology to either astrocytes or neurons.
Behaviorally, the Gfa2-CGG99 mice displayed an ab-
normal, shortened gait and were impaired in their ability
to skillfully walk along a horizontal ladder (i.e., ladder
rung task), slipping through the floor more often than
WT mice. These findings of a primary motor phenotype
in the Gfa2-CGG99 mice resemble the ataxia observed
in FXTAS patients. Unexpectedly, Gfa2-CGG99 mice
showed enhanced performance on the rotarod compared
to WT littermates that did not appear to be due to dif-
ferences in body weight. While superior rotarod per-
formance could reflect better motor learning, it could
also be due to use of an alternate strategy to stay on the
rotarod such as flipping, which was prevalent in Gfa2-
CGG99 mice. Enhanced performance on the rotarod by
transgenic and KO mice has been reported. For example,
neurexin-1α deletion [19], conditional knockout of
PTEN in cortex and hippocampus [37], overexpression
of human mutant α-Synuclein, SynA53T [41], and
Neuroligin-3 R451C knock-in mice [11] show enhanced
performance on the rotarod compared to WT mice. A
recent study reported that neuroligin-3 mutations in
mice increase repetitive behaviors through altered stri-
atal circuitry, and that this may manifest as stereotyped
behavior on the rotarod resulting in an apparent im-
provement in performance [45]. Therefore, it is possible
that the superior rotarod performance in Gfa2 mice is
the result of both better motor learning and the adop-
tion of repetitive behaviors on the rotarod such as flip-
ping, and that abnormal motor functions are part of the
phenotype of this novel Gfa2-CGG99 model of the Fra-
gile X premutation.
Gfa2-CGG99 mice showed widespread expression of
eGFP in more than 50% of all astroglia in the brain but
less than 0.5% of astrocytes showing eGFP fluorescence
had ubiquitin-positive inclusions. This is similar to the
CGG KI mouse model of FXTAS where relatively few
astrocytes develop ubiquitin-positive intranuclear
inclusions [56]. In contrast, 10–20% of astrocytes in
postmortem brain tissue from FXTAS patients containintranuclear inclusions, and there are more inclusions in
astrocytes than neurons in several brain region [23]. The
reasons for these differences in the prevalence of inclu-
sions in astrocytes and neurons, and between mouse
models of FXTAS and FXTAS are unknown. One possi-
bility may be differences in activity of the ubiquitin-
proteasome system (UPS) leading to the accumulation of
aggregated proteins within the ubiquitin-positive intra-
nuclear inclusions. The UPS is critical for intracellular
protein degradation and turnover, including clearing
cells of misfolded proteins. Moreover, UPS activity has
been reported to be lower in neurons compared to as-
trocytes and to decrease with age [53]. It is also possible
that inclusions form more slowly in astroglia than in
neurons in mouse brain, when compared to human neu-
rons and astrocytes.
Astroglia are known to play a major role in regulating
neuronal growth and synaptic development [12, 13, 44],
and also in the progression of neurodegenerative dis-
eases and neurodevelopmental disorders [33, 38, 49]. In
the present study, astroglia, including Bergmann glia,
that contained intranuclear inclusions appeared to
show lower levels of eGFP fluorescence in soma and
often an absence of eGFP in astrocyte processes. This
finding suggests eGFP expression may be reduced in
astroglia bearing ubiquitin-positive inclusions. A pos-
sible link between translational efficiency and CGG re-
peat number in carriers of premutation alleles has been
reported [43]. Specifically, FMR1 mRNA translational
efficiency was reduced in FXTAS patients with CGG re-
peat expansions in the range of 97–195 CGGs, with
translational efficiency directly correlated CGG repeat
length [43]. Therefore, it is possible that astroglia with
inclusions in the Gfa2-CGG99 mouse brain may have
reduced translational efficiency resulting in reduced ex-
pression of eGFP. Alternatively, eGFP mRNA or pro-
tein may be sequestered by the inclusions, thereby
reducing eGFP fluorescence, similar to the sequestra-
tion of several other proteins found to be associated
with inclusions in FXTAS [34, 48].
GFAP, the major intermediate filament protein, is al-
most exclusively expressed in astroglia, and is therefore
the preferred astrocyte marker in clinical and basic re-
search studies [17, 40]. Use of the GFAP promoter in the
present study was therefore expected to limit transgene
expression to astroglia. Previous reports have indicated
that some portions of both the human and murine pro-
moter may also direct expression of some genes in neu-
rons, but this occurred only in a few instances and not
for green fluorescent protein (GFP) [50]. Because intra-
nuclear inclusions were prevalent in distinct neuronal
populations, particularly in the hypothalamus, we carried
out a careful investigation of the specificity of eGFP/
GFAP expression in neurons with intranuclear
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staining we failed to find any evidence for expression of
eGFP or GFAP in neurons with inclusions. In addition,
we did not find expression of eGFP in microglia or
oligodendroglia, and this is consistent with a large num-
ber of studies using the GFAP promoter [50].
The finding that some neurons in Gfa2-CGG99 mice
also develop intranuclear inclusions but do not express
GFP opens the possibility that some form of cell-to-cell
transfer of pathology from astrocytes to neurons may be
occurring. One possibility is that either an RNA tran-
script or a translational product (e.g. FMRpolyG) is
transferred from astrocytes to adjacent neurons. This
could explain why inclusions in both astrocytes and neu-
rons stain for FMRpolyG. We do not yet have direct
evidence for such a mechanism in Gfa2-CGG99 mice or
in carriers of the Fragile X Premutation or in FXTAS.
However, cell-to-cell transmission of dipeptide repeat
proteins linked to translation of hexanucleotide repeat
expansions in ALS and FTD has been reported in vitro
in several CNS cell types, including induced pluripotent
stem cells from C9orf72-ALS patients. Importantly,
transmission was bidirectional, both from astrocytes to
neurons and from neurons to astrocytes [58]. Cell-to-
cell transfer processes have been reported in Alzheimer’s
pathology, Parkinson’s disease, and polyglutamine dis-
ease among others [16, 21, 39, 58].
Neurodegenerative diseases have been shown to ex-
hibit various forms of glial-neuronal miscommunication
in what has been called non-cell autonomous pathology
[21]. While cell-to-cell transfer of pathology may itself
be a form of non-cell autonomous pathology, it is also
possible that some other process associated with such
non-cell autonomous pathology may play a role in the
development of neuronal inclusions that are both ubi-
quitin and FMRpolyG positive. For example, it is known
that astrocytes play a critical role in regulating extracel-
lular neurotransmitter levels in the central nervous
system, including specific transport mechanisms for glu-
tamate and metabolic pathways for GABA [14]. Non-cell
autonomous pathology occurs in the polyglutamine re-
peat disease Spinocerebellar ataxia type 7 (SCA7), where
extensive pathology in Bergmann glia that help maintain
extracellular glutamate homeostasis results in glutamate
toxicity and subsequent neurodegeneration of cerebellar
Purkinje cells [15].
The finding that inclusions in both astrocytes and neu-
rons showed immunofluorescent labeling for FMRpolyG
supports the occurrence of repeat-associated non-ATG
(RAN) translation in Gfa2-CGG99 mice. RAN transla-
tion of a potentially toxic polyglycine-containing peptide,
FMRpolyG, has been previously reported in mouse
models of the fragile X premutation and in FXTAS post-
mortem tissue [9, 47, 52]. This peptide is translated fromthe expanded CGG repeat initiated at a non-canonical
ACG codon approximately 35 nucleotides upstream of
the start of the expanded CGG repeat segment [47]. The
mechanism of toxicity of FMRpolyG may involve disrup-
tion of the nuclear lamina of cells, and evidence suggests
that it is the carboxy-terminus of FMRpolyG that medi-
ates this toxicity [47]. RAN translation was originally de-
scribed for CAG/CTG repeat expansions within the
coding region of the ATXN8/ATXN8PS gene associated
with the neurodegenerative disorder spinocerebellar
ataxia type 8 (SCA8) [60]. RAN translation appears to
be a pathological mechanism in the hexanucleotide re-
peat expansion disorder C9orf72, the most common
genetic mutation associated with ALS-FTD [58], and
may also occur in the CAG repeat expansion disorder
Huntington’s disease [1]. Our results provide the first
evidence that RAN translation, and possible associated
pathology, also occurs in astroglia and Bergmann glia.
We performed extensive ultrastructural analysis of
the intranuclear inclusions found in astrocyte soma,
neurons, and the cytoplasm of astrocytes. We found
that the neuronal inclusions differ somewhat from
those in astrocytes, appearing as compact collections of
non-membrane bound granulo-filamentous material
often closely localized to the marginal chromatin of the
nucleus. Neuronal inclusions also appeared to be com-
posed of granulo-filamentous material but tended to be
located proximal to the nucleolus. In contrast, EM con-
firmed that intracytoplasmic inclusions were intracellu-
lar within astrocytic processes, with some having an
electron dense central core with a less dense peripheral
rim. These inclusions are similar to those described
earlier in neurons of the human hippocampus in post-
mortem tissue from FXTAS patients [24], and in dorsal
root ganglion cells [22]. Whether or not inclusions are
toxic, or how they contribute to neuropathology is cur-
rently unknown, but their association with reduced
eGFP expression in astrocytes and potential cell-to-cell
spreading from astrocytes to neurons suggest a role in
FXTAS disease pathogenesis.
Conclusions
Transgenic mice with high expression levels of an
expanded CGG-99 trinucleotide repeat driven by a
human Gfa2 promoter were developed to examine
pathology in glia associated with the Fragile X premuta-
tion. Expression in glia was widespread throughout the
brain, as visualized by the eGFP reporter expression
within the Gfa2-CGG99-eGFP construct. eGFP fluores-
cence was limited to astroglia and Bergmann glia only,
and a subset of these glia also developed ubiquitin-
positive intranuclear inclusions between the ages of 4–
16 months. Expression of eGFP was not observed in
microglia immunolabeled with Iba1 or oligodendroglia
Wenzel et al. Acta Neuropathologica Communications            (2019) 7:27 Page 20 of 22immunolabeled with MBP, and intranuclear inclusions
were never observed in these glial subtypes. Although
we do not yet have direct evidence for cell-to-cell
spread of pathology, the unexpected finding of intra-
nuclear inclusions in NeuN-labelled neurons, particu-
larly in the hypothalamus, opens the possibility for this
type of transfer of pathology in our Gfa2-CGG99
mouse model of FXTAS. The presence of the RAN
translation product FMRpolyG in the astrocyte inclu-
sions indicates that this mechanism of pathology in tri-
nucleotide repeat expansion disease may not be limited
to neurons, and may occur in astrocytes in FXTAS pa-
tients, though this is yet to be documented. Taken to-
gether, our results highlight that FXTAS pathology is
complex involving both astrocytes and neurons and
their possible interactions. Our findings thus provide
important new insights that should be considered when
developing therapies for FXTAS in human patients.
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